Anixa Biosciences宣布,其针对卵巢癌的CAR-T细胞疗法临床试验取得鼓舞人心的患者生存观察结果。公司同时获得监管机构批准,得以实施重大剂量递增方案,为后续疗效评估提供关键支持。
Anixa Biosciences宣布,其针对卵巢癌的CAR-T细胞疗法临床试验取得鼓舞人心的患者生存观察结果。公司同时获得监管机构批准,得以实施重大剂量递增方案,为后续疗效评估提供关键支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.